Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) EBITDA Margin (2021 - 2023)

Senti Biosciences has reported EBITDA Margin over the past 3 years, most recently at 4415.09% for Q3 2023.

  • For Q3 2023, EBITDA Margin fell 331746.0% year-over-year to 4415.09%; the TTM value through Jun 2024 reached 16850.0%, down 1465870.0%, while the annual FY2025 figure was 279263.64%, N/A changed from the prior year.
  • EBITDA Margin for Q3 2023 was 4415.09% at Senti Biosciences, down from 2721.98% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 9533.51% in Q4 2022 and troughed at 4415.09% in Q3 2023.
  • A 3-year average of 622.15% and a median of 1236.33% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: soared 1090854bps in 2022 and later crashed -331746bps in 2023.
  • Year by year, EBITDA Margin stood at 1375.03% in 2021, then soared by 793bps to 9533.51% in 2022, then crashed by -146bps to 4415.09% in 2023.
  • Business Quant data shows EBITDA Margin for SNTI at 4415.09% in Q3 2023, 2721.98% in Q2 2023, and 1455.68% in Q1 2023.